PharmaDrug (CSE: PHRX) this morning revealed the strategic plans for its Sairiyo Therapeutics subsidiary in relation to the clinical development of...
Vous n'êtes pas connecté
Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study in Australia. The trial aims to assess a reformulated version of oral cepharanthine, referred to as PD-001, as a treatment for cancer and medical countermeasures. The post PharmaDrug Joint Venture Receives Approval For Phase 1 Clinical Trial appeared first on the deep dive.
PharmaDrug (CSE: PHRX) this morning revealed the strategic plans for its Sairiyo Therapeutics subsidiary in relation to the clinical development of...
Revive Therapeutics (CSE: RVV) is continuing its efforts into evaluating the uses of Bucillamine, disclosing yesterday an update to its The post...
Madrigal's blockbuster drug gaining FDA approval this March has opened the doors to a wave of therapeutics from Eli Lilly, Boehringer Ingelheim,...
MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
SINGAPORE Airlines has received Indian government approval for foreign direct investment, clearing a significant hurdle in the merger of airline...
Mainstream Renewable Power, the pureplay global wind and solar company majority-owned by Aker Horizons, announced that the joint venture KF Wind, a...
Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...
VANCOUVER, British Columbia, Sept. 06, 2024 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V:WHN) is pleased to announce the Company has received...